The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
about
Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cellsExpression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinomaCytokine-Induced Modulation of Colorectal CancerPrognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon CancerAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyVascular endothelial growth factor-B in physiology and diseaseThe tumor as an organ: comprehensive spatial and temporal modeling of the tumor and its microenvironmentRole of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer.Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein arrayExpression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancerSuppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.Expression of vascular endothelial growth factors A and C in human pancreatic cancer.Lymphangiogenesis and lymphatic metastasis in breast cancer.A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancerImpact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancerClinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family membersExploring novel KDR inhibitors based on pharmaco-informatics methodology.The biophysical property of A549 cells transferred by VEGF-D.The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer.Ziv-aflibercept in metastatic colorectal cancerThe association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancerExpression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors.Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.Roles of main pro- and anti-angiogenic factors in tumor angiogenesisComprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model.The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancerPlasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma.Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in miceExpression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.Revealing the role of VEGFA in clear cell sarcoma of the kidney by protein-protein interaction network and significant pathway analysis.Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer.The role of the VEGF-C/VEGFRs axis in tumor progression and therapy.The role of the VEGF-C/VEGFR-3 axis in cancer progression.Tumour-associated angiogenesis in human colorectal cancer.Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practiceExpression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.
P2860
Q24297590-0AC2027B-36EB-42D7-B7B0-9EFE661DD284Q24805206-BD94D315-3508-493F-A32C-2A7274213A2FQ26752374-6A08E046-A5D6-4C72-B87F-8EE285D08B55Q26777108-AEF23CB4-3324-4FFD-BB21-E99432A20543Q26853604-4CF14FDE-AFA6-4BFC-BFCD-7C1FE64B21CCQ27003400-09650014-12EE-4401-A442-2B42A27D8D16Q27318697-6B7CDDB9-F3AC-4F36-A486-9A1A619E53ADQ33539996-BFFCE281-0783-49DE-A394-E1892E7738A0Q33688120-5B9C225F-7528-4275-9566-1CEFF15D0DC6Q33745294-2D6475B1-5311-4539-8622-6C09CE5380CAQ33760923-1800BCF5-5EB2-478A-8706-A8D9A69CD694Q33788147-20CF5C84-7063-4FE3-BD76-14FBB5B245CEQ33940058-3477859D-3A20-4434-85F7-78D2D02AC4E6Q34224045-A305497F-8B01-477D-B7BC-03060FD1AB86Q34360263-FBD8EDEA-9492-4EFF-A049-5D7941D5A89FQ34475764-E7B32926-60F3-4BB6-B243-BBCC1C8D23BAQ34600778-A769506F-EF90-409B-993D-3412FB2E4419Q34633821-875A721D-CF94-4868-9DCF-2215B5BC0BFDQ34651210-8093AD08-578C-4E2B-B7CC-9E6DE159699AQ34658579-5EF9A262-E8FF-4791-915C-4EF4882C3BE8Q35021680-6550EA77-9196-4F9F-96DE-AD3266F7E14EQ35103259-AFF9DB32-8B25-47B9-8519-992D135B1F47Q35104008-893206EC-C2FF-42B5-B7BB-9314BAC6721AQ35113402-AB36D013-4952-4D17-9D89-581D6562D36FQ35587630-7CDE3E49-C87B-4531-982A-F640B0834224Q35603983-2F916F32-1AD9-42FF-A047-008D44D1DF10Q35668936-F0D7590D-5DE6-4F07-BE3E-7B8D78446D67Q36021081-9A1808D6-FDD5-41E9-8B0B-CA4E0EDB35BEQ36023363-665A4D98-75F5-424A-B4CD-760582729BDAQ36429573-2579CE99-819C-4A81-9722-BF34CD4D3DA2Q36486025-07E3C719-F9E1-4614-AD93-A090D6A51E9CQ36502541-920E7020-751B-43E0-952F-F5F55C8D9F52Q36524455-BDCD9FAF-8D93-41FB-ACCE-C402CE1E5807Q36549454-110B814C-4811-4475-85B3-D48173B70836Q36589860-2CEAE7CF-7BFE-40A3-8CE0-761657C10889Q36609889-0F477CE3-C14D-43B1-983D-64D150CC8748Q36689348-391B9B2F-08EE-4934-91F7-D063D0EAF5ACQ37132680-CFCA1D78-EAF5-4041-883C-3D725272DB18Q37424106-037C5916-A1E6-4FB8-AC40-1A42113AAC58Q37571729-0170C277-337A-4810-BD93-3EA0D309A215
P2860
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The angiogenic switch for vasc ...... colorectal cancer progression.
@en
The angiogenic switch for vasc ...... colorectal cancer progression.
@nl
type
label
The angiogenic switch for vasc ...... colorectal cancer progression.
@en
The angiogenic switch for vasc ...... colorectal cancer progression.
@nl
prefLabel
The angiogenic switch for vasc ...... colorectal cancer progression.
@en
The angiogenic switch for vasc ...... colorectal cancer progression.
@nl
P2093
P2860
P50
P356
P1476
The angiogenic switch for vasc ...... colorectal cancer progression.
@en
P2093
Helen R Morrin
Prudence A E Scott
Sarah P Gunningham
Vickie Hanrahan
P2860
P304
P356
10.1002/PATH.1339
P577
2003-06-01T00:00:00Z